ADMA Biologics (ADMA) AI Stock Analysis

• Market Cap: $3.91B
• Dividend Yield: N/A
• Average Volume (3M): 2.88M
• Price to Earnings (P/E): 19.3
• Beta (1Y): 0.97
• Revenue Growth: 43.58%
• EPS Growth: 491.01%
• Country: US
• Employees: 685
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.15
• Shares Outstanding: 238,630,720
• 10 Day Avg. Volume: 4,141,711
• 30 Day Avg. Volume: 2,879,133
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 9.53
• Enterprise Value/Gross Profit: 17.99
• Enterprise Value/Ebitda: 27.72
• 1Y Price Target: $19.00
• Price Target Upside: 10.47% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: $19.00 ▲(10.47% Upside)

ADMA Biologics exhibits strong financial performance and promising earnings call insights, driving the overall score. Technical analysis presents mixed signals, while valuation remains fair. The company's strategic initiatives and robust guidance further bolster its position.

Positive Factors

Production Expansion

Expansion of collection centers from 50-70 to over 250 increases raw plasma acquisition capabilities.

Supply Chain

Long-term plasma supply agreements have set the stage for achieving over $1 billion in sales by 2030.

Negative Factors

Filing Delay

ADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.

Filing Uncertainty

The filing of ADMA's 10-K is seen as a clearing event, resolving previous accounting concerns and shifting focus to the expansion of ASCENIV.

ADMA Biologics Business Overview & Revenue Model

Company Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

How the Company Makes Money

ADMA Biologics generates revenue primarily through the sale of its immunoglobulin products to hospitals, clinics, and specialty distributors. The company benefits from a diverse revenue model that includes direct sales to healthcare providers and potentially through partnerships with other pharmaceutical companies for distribution and co-marketing of its products. Additionally, ADMA may receive revenue from government contracts or grants aimed at supporting its research and development efforts. Strategic partnerships and collaborations with other healthcare organizations are also key contributors to its earnings, as these can provide access to new markets and enhance product distribution capabilities.

ADMA Biologics Financial Statement Overview

Summary

ADMA Biologics demonstrates strong financial health with significant improvements in revenue growth and profitability. The company maintains a solid balance sheet with low leverage and high equity ratios, minimizing financial risk. Strong cash flow management supports its operations, although careful monitoring of cash reserves is advisable.

Income Statement

ADMA Biologics has shown impressive revenue growth, with a TTM increase in Total Revenue of 7.72% compared to the previous annual report. The company has achieved a Gross Profit Margin of 52.54% and a Net Profit Margin of 45.00% in the TTM period, indicating strong profitability. The EBIT and EBITDA margins at 33.08% and 34.46% respectively, further demonstrate efficient operational management. Overall, the income statement reflects a solid turnaround from previous losses, showcasing strong growth and profitability.

Balance Sheet

ADMA Biologics has a strong equity position, with Stockholders' Equity accounting for 73.13% of Total Assets in the TTM period. The Debt-to-Equity Ratio is 0.22, indicating a low reliance on debt financing, which mitigates financial risk. However, the decreasing cash and short-term investments over time warrant attention. The Return on Equity of 55.39% in the TTM period is exceptionally high, reflecting strong profitability relative to equity.

Cash Flow

The company has shown strong cash flow management with a Free Cash Flow to Net Income Ratio of 0.44 in the TTM period, indicating efficient conversion of income to cash. While Operating Cash Flow decreased slightly from the previous period, it remains robust and supports the company's operations. The Free Cash Flow Growth Rate shows a decrease compared to previous years, highlighting the need for cautious cash management in future periods.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	474.17M	426.45M	258.21M	154.08M	80.94M	42.22M
Gross Profit	251.32M	219.55M	88.94M	35.27M	1.17M	-19.07M
EBITDA	163.11M	147.69M	5.12M	-39.72M	-53.33M	-59.82M
Net Income	208.93M	197.67M	-28.24M	-85.18M	-84.45M	-87.61M
Balance Sheet
Total Assets	558.38M	488.68M	329.18M	348.46M	276.25M	207.67M
Cash, Cash Equivalents and Short-Term Investments	90.28M	103.15M	51.35M	86.52M	51.09M	55.92M
Total Debt	83.83M	82.12M	141.42M	154.44M	102.92M	97.67M
Total Liabilities	160.06M	139.66M	193.98M	196.49M	135.08M	119.42M
Stockholders Equity	398.32M	349.02M	135.21M	151.97M	141.17M	88.25M
Cash Flow
Free Cash Flow	66.09M	110.10M	3.82M	-73.42M	-125.88M	-114.73M
Operating Cash Flow	76.71M	118.67M	8.80M	-59.51M	-112.37M	-102.00M
Investing Cash Flow	-11.10M	-8.57M	-4.98M	-13.91M	-13.51M	-12.72M
Financing Cash Flow	-63.57M	-58.30M	-38.99M	108.85M	121.05M	143.90M

ADMA Biologics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMA, the sentiment is Negative. The current price of 17.2 is below the 20-day moving average (MA) of 17.75, below the 50-day MA of 18.50, and below the 200-day MA of 18.79, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 43.74 is Neutral, neither overbought nor oversold. The STOCH value of 38.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADMA.

ADMA Biologics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	74 Outperform	$3.91B	19.29	71.23%	―	43.58%	491.01%
VRNA	68 Neutral	$9.05B	―	-36.38%	―	―	34.29%
IONS	54 Neutral	$6.51B	―	-59.83%	―	16.04%	30.61%
ZLAB	54 Neutral	$3.81B	―	-28.39%	―	32.56%	33.33%
Sector *	51 Neutral	$7.42B	-0.36	-40.86%	2.27%	22.89%	-2.16%
PCVX	50 Neutral	$3.89B	―	-21.65%	―	―	11.84%
CYTK	43 Neutral	$4.11B	―	435.49%	―	2635.74%	4.66%

ADMA Biologics Corporate Events

ADMA Biologics Secures $300M Credit Agreement with JPMorgan

On August 5, 2025, ADMA Biologics entered into a $300 million credit agreement with JPMorgan Chase Bank, which includes a $75 million term loan and a $225 million revolving credit facility. This refinancing replaces existing debt, lowers borrowing costs, and enhances strategic financial flexibility. Additionally, ADMA reported strong financial results for the second quarter of 2025, with a 14% year-over-year revenue increase and significant earnings growth. The company also initiated commercial-scale manufacturing with an FDA-approved process, acquired a new facility to expand its U.S. supply chain, and repurchased $15 million in common stock, positioning itself for accelerated growth in the latter half of 2025 and beyond.

The most recent analyst rating on (ADMA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.

ADMA Biologics Holds Annual Stockholders Meeting

On June 4, 2025, ADMA Biologics, Inc. held its Annual Meeting of Stockholders, where key decisions were made, including the election of two Class III directors, ratification of KPMG LLP as the independent public accounting firm for 2025, approval of executive compensation, and setting the frequency of future advisory votes on executive pay to annually. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (ADMA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.